TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Dr. Nikita M. Patel
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

A peer-reviewed study published in Cytotherapy explores the potential of mesenchymal stromal cell (MSC) therapies, focusing on systemic delivery, local delivery methods, and in vivo persistence of cell treatments.

Insights
ADP   neutral

Mentioned in article header but no substantive information provided about company performance


INMB   positive

The company is advancing research in stromal cell therapies, with a promising platform (CORDStrom) targeting inflammatory and degenerative diseases, and plans to file regulatory applications in 2026